Print

Simcere Pharmaceutical Group's Diosmectite API Passes EU-GMP Inspection  
4/22/2010 10:49:57 AM

NANJING, China, April 21 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE:SCR - News), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that its diosmectite, the Active Pharmaceutical Ingredient (API) in Simcere's branded generic drug Biqi, has passed EU-GMP inspection. This enables Simcere to market diosmectite in the European Union countries.
//-->